Daiichi-Sankyo Company Limited

 

Feb 10, 2012

OVERVIEW |  NEWS |  MULTIMEDIA  | RESEARCH


 

Daiichi-Sankyo Company Limited Company Summary

Daiichi Sankyo Company, Limited was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world.
 

COMPANY DATA

 
Company Headquarters 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 
    103-8426, Japan 
Company Telephone 81-3-6225-1111 
Company Principal Sector Health & Pharm 
Company Principal Industry Pharmaceutical 
Company Homepage www.daiichisankyo.co.jp
 

Key Developments: Daiichi-Sankyo Company Limited
 Asian Markets Overview of December 9
DEC 9, 2009 13:30 - Article Views: 6,043
US stocks fell on Tuesday on disappointing corporate news and renewed worries over global credit markets. Asian stocks mostly opened lower today with Australian and Japanese markets slashed sharply at opening.
 Australian Market Report of March 30: A Slowdown after Weeks of Rallies
MAR 30, 2009 13:00 - Article Views: 6,708
The Australian share closed slightly higher lifted by miners. The benchmark S&P/ASX200 index ended the day up 0.7%, or 25.7 points, at 3672.3, while the broader All Ordinaries index rose 0.8%, or 29.3 points, at 3615.6. For the week, the ASX200 added 6% and the All Ordinaries rose 6.2%.
 Biota Holdings Limited (ASX:BTA) Daiichi-Sankyo (TYO:4568) Exercise Right To Market CS-8958 In Japan
MAR 30, 2009 09:41 - Article Views: 3,574
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that Daiichi Sankyo (TYO:4568), the co-owner of the long acting neuraminidase inhibitor (LANI) CS-8958, has signed a contract to manufacture and market the product in Japan, pending the successful completion of the pivotal Phase III clinical studies and on obtaining registration approval. Biota, as one of the owners, will receive an undisclosed royalty on sales and a number of fixed sum payments on the achievement of certain sales milestones in the Japanese market.
 Asian Market Overview of January 23
JAN 23, 2009 15:00 - Article Views: 8,264
Tokyo stocks opened sharply lower Friday with investor sentiment hurt by Sony Corp.'s forecast of an annual operating loss as well as by a fall in U.S. shares overnight due to disappointing corporate earnings there. Yesterday the Aisan markets gained on the good lead from Wall Street. Hong Kong's Hang Seng Index firmed 0.6% to 12657.99. The Shanghai Composite Index added 1%. South Korea's Kospi Composite rose 1.1% to 1116.23.
 Australian Market Report of January 22: Helped by Short Selling Ban
JAN 22, 2009 13:00 - Article Views: 8,482
Yesterday the Australian stock market ended the day lower, led by financial stocks, on renewed worries about banking industry worldwide. The benchmark S&P/ASX200 index was down 1%, or 33.8 points, at 3442.8, while the broader All Ordinaries index was lower by 0.9%, or 30.2 points, at 3394.8. Regulator ASIC's move to extend a ban on covered short-selling of financial securities would give a positive lead to the banking industry.
 Biota Holdings Limited (ASX:BTA) LANI Phase III Clinical Trials Set For Enrolment
NOV 17, 2008 12:02 - Article Views: 5,067
Biota Holdings Limited (ASX:BTA)(PNK:BTAHY) today announced that the multiple centres involved in the Phase III clinical trail on its long acting neuraminidase inhibitor (LANI) CS-8958 are ready to commence treatment. Patients are expected to enrol into the study progressively throughout the Asian influenza season.
 Biota Holdings Limited (ASX:BTA) LANI Phase II completed - Phase III scheduled
JULY 31, 2008 09:41 - Article Views: 2,394
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that its second generation, influenza treatment, CS-8958, has successfully completed its initial Phase II clinical evaluation, showing favourable outcomes against all measured endpoints. The initial Phase III trial is scheduled to commence later this year. CS-8958 is a long acting neuraminidase inhibitor (LANI), and is co-owned with Daiichi-Sankyo Company Limited (TYO:4568).

23,640 COMPANY PROFILE VIEWS

 
This Page Viewed: (Last 7 Days: 32) (Last 30 Days: 138) (Since Published: 3254) 
 

Site Search

 
 ENGLISH   All Languages

View in Other Languages

      

MARKETS

 

 NIKKEI 225
TYO:4568
Delayed Data:
Chart by Google

ABN Newswire on iPhone/iPad

Download from Apple

Mobile Video TV

qrcode
Scan with your Mobile Phone to view ABN Newswire Video Channel on Mobile
 
City Index - A Better Way To Trade